The price of shares in FTSE 100 pharmaceutical giant AstraZeneca (LON:AZN) climbed 2.13% to 7,480p (as of 09:25 GMT) after it sold the rights to two drugs in over 70 countries in a deal valued at $400 million. The consideration will consist of an upfront $250 million with non-contingent payments of the remainder of the sum during the first half of this year.